Viewing Study NCT06844357


Ignite Creation Date: 2025-12-24 @ 6:51 PM
Ignite Modification Date: 2025-12-25 @ 4:23 PM
Study NCT ID: NCT06844357
Status: RECRUITING
Last Update Posted: 2025-04-06
First Post: 2025-02-19
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Sponsor: Zhejiang Raygene Pharmaceuticals Co., Ltd
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module